ع
The network meta-analysis published in The Lancet Psychiatry evaluated more than a dozen widely prescribed antidepressants and placed escitalopram at the top for maintaining symptom-free status in patients with major depressive disorder. Agomelatine and duloxetine followed closely in the rankings while fluoxetine came in just below those two options. Patients assigned to escitalopram showed higher rates of sustained improvement and lower discontinuation compared with many alternatives although the overall differences remained modest according to the findings.
A separate assessment published in the Annual Review of Clinical Psychology placed lifetime recurrence rates for those who experience an initial depressive episode as high as 75 to 90 percent. Data from a meta-analysis in the International Journal of Neuropsychopharmacology indicated that continued antidepressant use after initial response produced a relative risk reduction yielding a number needed to treat of roughly four to avert one additional relapse. Such figures align with broader evidence that major depressive disorder often follows a recurrent course without ongoing intervention.
Earlier randomized trials have repeatedly tested escitalopram against placebo in relapse-prevention settings. A 2007 study involving adults aged 65 and older reported in The American Journal of Geriatric Psychiatry found that only 9 percent of those continuing escitalopram relapsed over six months compared with 33 percent switched to placebo. The same investigation recorded a fourfold reduction in relapse risk for the active-treatment arm and noted good tolerability throughout the continuation phase.
Additional research has explored escitalopram maintenance across different populations and durations. A 2006 trial focused on generalized anxiety disorder but with overlapping depressive features showed a 19 percent relapse rate on escitalopram versus 56 percent on placebo over six to 18 months according to findings published in the International Clinical Psychopharmacology journal. Pooled parametric survival analyses conducted in 2020 and catalogued on PubMed further suggested that most of the preventive benefit from antidepressants accumulates within the first six months after remission while gains beyond that window become harder to distinguish from placebo.
Economic assessments tied to recurrent depression highlight substantial societal costs that effective maintenance therapy might mitigate. One review cited in the Annual Review of Clinical Psychology placed annual U.S. economic burdens linked to major depressive disorder above 325 billion dollars with recurrence driving a sizable share of those expenses. Systematic reviews that examined both pharmacological and psychosocial approaches reported one-year relapse-free survival around 76 percent with active medication versus 56 percent with placebo in aggregated trial data.
Clinicians have long emphasized individualized treatment decisions rather than uniform switches based on aggregate rankings. The Lancet Psychiatry analysis itself cautioned that all evaluated antidepressants demonstrated some efficacy and that factors such as side-effect profiles patient history and concurrent conditions should guide prescribing. Longer-term studies beyond one year remain necessary to clarify whether initial advantages persist according to the authors who called for continued research into optimal maintenance strategies.
